A Phase 3 clinical trial testing ianalumab (VAY736) in combination with Promacta (eltrombopag) in people with primary immune thrombocytopenia…
Marisa Wexler MS
Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler MS
VON WILLEBRAND DISEASE
NewsMore Haemate-P use could mean big cost savings for Spain: Study
Increasing the use of Haemate-P to treat von Willebrand disease (VWD) could yield substantial savings for the healthcare system…
VON WILLEBRAND DISEASE
NewsDental procedures may lead to bleeding in VWD, hemophilia
People with von Willebrand disease (VWD) or hemophilia may experience bleeding complications after dental procedures, a new study highlights.